0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Panobinostat, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2015-08-28
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No